Filing Details
Spyre Therapeutics, Inc. (NASDAQ:SYRE) filed a Form 8-K with the Securities and Exchange Commission on October 07, 2026, disclosing a material event.
8k filedNASDAQ:SYRE
Spyre Therapeutics, Inc. (SYRE) Reports Material Event to SEC
Spyre Therapeutics, Inc. (NASDAQ:SYRE) filed a Form 8-K with the Securities and Exchange Commission on October 07, 2026, disclosing a material event.
At publication ·
What changed
Spyre Therapeutics, Inc. (NASDAQ:SYRE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Spyre Therapeutics filed a Form 8-K on October 7, 2026, disclosing a material event to the SEC.
- The stock trades at $80.85 with a market capitalization of $2.1 billion.
- Material events in 8-K filings can include leadership changes, acquisitions, asset sales, or financial guidance changes.
Market Context
Spyre Therapeutics, Inc.'s stock currently trades at $80.85 with a market capitalization of $2.1B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Spyre Therapeutics, Inc.'s stock.
All SEC filings for Spyre Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SYRE Stock Page
Frequently Asked Questions
Where can I read SYRE's SEC filings?
Browse all filings on our SYRE SEC filings page.
What types of SEC filings does Spyre Therapeutics, Inc. file?
Public companies like Spyre Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.